Propanc Biopharma (OTCMKTS:PPCB) versus Entrada Therapeutics (NASDAQ:TRDA) Head-To-Head Contrast

Propanc Biopharma (OTCMKTS:PPCB) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.

Profitability

This table compares Propanc Biopharma and Entrada Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Propanc Biopharma	N/A	-3,652.66%	-971.09%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

Volatility and Risk

Propanc Biopharma has a beta of 3.59, meaning that its stock price is 259% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.09, meaning that its stock price is 109% less volatile than the S&P 500.

Institutional and Insider Ownership

86.4% of Entrada Therapeutics shares are held by institutional investors. 28.5% of Propanc Biopharma shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Propanc Biopharma and Entrada Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Propanc Biopharma	0	0	0	0	0.00
Entrada Therapeutics	1	2	2	1	2.50

Entrada Therapeutics has a consensus target price of $18.25, suggesting a potential upside of 188.08%. Given Entrada Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Entrada Therapeutics is more favorable than Propanc Biopharma.

Valuation and Earnings

This table compares Propanc Biopharma and Entrada Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Propanc Biopharma	N/A	N/A	-$1.82 million	($13.19)	0.00
Entrada Therapeutics	$25.42 million	9.67	-$143.75 million	($3.99)	-1.59

Propanc Biopharma has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than Propanc Biopharma, indicating that it is currently the more affordable of the two stocks.

Summary

Entrada Therapeutics beats Propanc Biopharma on 9 of the 14 factors compared between the two stocks.

About Propanc Biopharma

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

About Entrada Therapeutics

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.